The heterogeneous nature of the mechanisms underlying neuropathic pain complicates the selection of appropriate treatments for individual patients. Although systematic reviews have outlined the ...

Finnerup NB, Kuner R, Jensen TS: Neuropathic pain: from mechanisms to treatment. Physiol Rev 2021; 101: 259–301 CrossRef MEDLINE 9. Gangadharan V, Zheng H, Taberner FJ, et al.: Neuropathic pain ...

Cellular research indicates that neuropilin-1 plays a crucial role in pain signaling, presenting a potential pathway for ...

The focus of traditional treatments on the symptoms rather than the condition has unfortunately made neuropathy a ...

For people suffering from chronic knee pain, especially those over 50, a new treatment is offering hope and relief.

Nerve pain is distinct from typical tissue pain ... to determine the underlying cause of your pain and the best treatment option for you.

Treatment with XG005 resulted in statistically significant and clinically meaningful reduction in post-surgical pain ...

AFA-281 is under clinical development by AfaSci and currently in Phase I for Neuropathic Pain (Neuralgia). According to GlobalData, Phase I drugs for Neuropathic Pain (Neuralgia) have a 76% phase ...

Earlier this year, Vertex initiated its suzetrigine pivotal program in painful diabetic peripheral neuropathy (DPN), another type of peripheral neuropathic pain (PNP). That study is ongoing.